Kehua Bio-Engineering: The information released by self-media is false; the company is not involved in immune cell therapy business.

MetaMuskRat · 2026-03-25T23:17:18+00:00

People Finance News, March 25 — An investor asked Kehua Bio on an interactive platform: "Multiple self-media outlets have published reports that Tencent invested in Kehua Bio to promote the commercialization of CAR-T immunotherapy, participate in related clinical trials, and increase investment in solid tumor cell therapy research and development. Is this true?" In response, Kehua Bio replied that the matters described in the question are not true. The company focuses on the in vitro diagnostics industry, with its main business being the research and development, production, and sales of in vitro diagnostic reagents and medical testing instruments, and does not involve immunotherapy business.

MetaMuskRat

2026-03-25 23:17:18

People’s Financial News, March 25 — An investor asked KeHua Bio on the interactive platform: “Multiple media outlets have reported that Tencent invested in KeHua Bio to promote the commercialization of CAR-T immunotherapy, participate in related clinical trials, and increase R&D in solid tumor cell therapy. Is this true?” In response, KeHua Bio stated that the information is not true. The company is focused on the in vitro diagnostics industry, with main businesses including the research, production, and sales of in vitro diagnostic reagents and medical testing instruments. It is not involved in immunotherapy treatments.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.